[The progress of KIF5B-RET fusion gene in non-small cell lung cancer].
作者信息
Jin Lin-ling, Kong Hui, Xie Wei-ping
出版信息
Zhonghua Jie He He Hu Xi Za Zhi. 2013 Jul;36(7):524-6.
PMID:24262090
Abstract
摘要
相似文献
1
[The progress of KIF5B-RET fusion gene in non-small cell lung cancer].
Zhonghua Jie He He Hu Xi Za Zhi. 2013 Jul;36(7):524-6.
2
The KIF5B-RET Fusion Gene Mutation as a Novel Mechanism of Acquired EGFR Tyrosine Kinase Inhibitor Resistance in Lung Adenocarcinoma.
Clin Lung Cancer. 2019 Jan;20(1):e73-e76. doi: 10.1016/j.cllc.2018.09.011. Epub 2018 Sep 21.
3
Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer.
Mol Cancer Ther. 2014 Dec;13(12):2910-8. doi: 10.1158/1535-7163.MCT-14-0274. Epub 2014 Oct 27.
4
How should "RET positive" NSCLC be treated?
Lung Cancer. 2017 Jun;108:250-251. doi: 10.1016/j.lungcan.2017.02.006. Epub 2017 Feb 6.
5
Progress in Discovery of KIF5B-RET Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer.
J Med Chem. 2015 May 14;58(9):3672-81. doi: 10.1021/jm501464c. Epub 2015 Feb 4.
6
Sorafenib treatment for patients with RET fusion-positive non-small cell lung cancer.
Lung Cancer. 2016 Mar;93:43-6. doi: 10.1016/j.lungcan.2015.12.011. Epub 2015 Dec 30.
7
WAC/RET: A Novel RET Oncogenic Fusion Variant in Non-Small Cell Lung Carcinoma.
J Thorac Oncol. 2018 Jul;13(7):e122-e123. doi: 10.1016/j.jtho.2018.03.003.
8
RET fusions in non-small-cell lung cancer: an emerging target reshaping the treatment paradigm.
Future Oncol. 2021 Apr;17(12):1445-1448. doi: 10.2217/fon-2020-1297. Epub 2021 Feb 12.
9
Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer.
J Thorac Oncol. 2018 Jan;13(1):27-45. doi: 10.1016/j.jtho.2017.10.021. Epub 2017 Nov 8.
10
Novel Human-Derived Fusion NSCLC Cell Lines Have Heterogeneous Responses to RET Inhibitors and Differential Regulation of Downstream Signaling.
Mol Pharmacol. 2021 Jun;99(6):435-447. doi: 10.1124/molpharm.120.000207. Epub 2021 Apr 1.
Zotero 插件